JOUNCE THERAPEUTICS INC (JNCE)
US4811161011 - Common Stock
Taking everything into account, JNCE scores 3 out of 10 in our fundamental rating. JNCE was compared to 588 industry peers in the Biotechnology industry. JNCE has a great financial health rating, but its profitability evaluates not so good. JNCE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
JNCE had negative earnings in the past year.
In the past year JNCE has reported a negative cash flow from operations.
In the past 5 years JNCE reported 4 times negative net income.
In the past 5 years JNCE always reported negative operating cash flow.
1.2 Ratios
The profitability ratios for JNCE are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
JNCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
JNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, JNCE has more shares outstanding
The number of shares outstanding for JNCE has been increased compared to 5 years ago.
JNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 0.64, we must say that JNCE is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.64, JNCE is doing good in the industry, outperforming 60.92% of the companies in the same industry.
There is no outstanding debt for JNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.64 |
ROIC/WACCN/A
WACC8.03%
2.3 Liquidity
JNCE has a Current Ratio of 8.37. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
JNCE has a Current ratio of 8.37. This is in the better half of the industry: JNCE outperforms 68.35% of its industry peers.
A Quick Ratio of 8.37 indicates that JNCE has no problem at all paying its short term obligations.
JNCE has a Quick ratio of 8.37. This is in the better half of the industry: JNCE outperforms 68.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.37 | ||
| Quick Ratio | 8.37 |
3. Growth
3.1 Past
JNCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.20%, which is quite impressive.
Looking at the last year, JNCE shows a very strong growth in Revenue. The Revenue has grown by 205.20%.
JNCE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.75% yearly.
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q266.1%
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y2.75%
Revenue growth Q2QN/A
3.2 Future
JNCE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.92% yearly.
The Revenue is expected to grow by 48.27% on average over the next years. This is a very strong growth
EPS Next Y-37.55%
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
EPS Next 5Y6.92%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y36.37%
Revenue Next 5Y48.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for JNCE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JNCE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as JNCE's earnings are expected to decrease with -8.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
5. Dividend
5.1 Amount
No dividends for JNCE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JOUNCE THERAPEUTICS INC
NASDAQ:JNCE (5/3/2023, 7:26:07 PM)
After market: 1.92 +0.04 (+2.13%)1.88
-0.05 (-2.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap98.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.37 | ||
| Quick Ratio | 8.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-37.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y